IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v3y2019i1d10.1007_s41669-018-0085-0.html
   My bibliography  Save this article

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use

Author

Listed:
  • Alex Diamantopoulos

    (Symmetron Limited, Kinetic Centre)

  • Toby M. Maher

    (NIHR Biomedical Research Unit Royal Brompton Hospital
    Imperial College London)

  • Nils Schoof

    (Boehringer Ingelheim GmbH)

  • Dirk Esser

    (Boehringer Ingelheim GmbH)

  • Corinne LeReun

    (Independent Statistician)

Abstract

Background Disease progression and acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) are associated with high morbidity and mortality. They usually require a visit to a specialist or a general practitioner (GP) in less severe cases or hospitalisation in more severe cases. Objective The objective of this study was to identify factors that influence resource use in IPF. Methods Clinical and healthcare resource use data were collected in two large, international, multi-centre, randomised controlled trials (RCTs) that studied nintedanib for the treatment of IPF (INPULSIS-1 and -2). The pooled data of nintedanib and placebo included 1014 patients followed for 12 months. The trial data were analysed in 3-month intervals. We studied two dependent variables: the occurrence of all-cause hospitalisation and visits to a physician (GP or specialist). The independent variables included the change in forced vital capacity percent predicted (FVC%pred), investigator-reported acute exacerbation events, age, time since diagnosis, smoking status, and sex. Results Hospitalisation during a 3-month interval was significantly associated with a drop of at least 5 or 10 points in FVC%pred (odds ratios [ORs] 1.58 [p = 0.009] and 2.62 [p

Suggested Citation

  • Alex Diamantopoulos & Toby M. Maher & Nils Schoof & Dirk Esser & Corinne LeReun, 2019. "Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use," PharmacoEconomics - Open, Springer, vol. 3(1), pages 81-91, March.
    • Handle: RePEc:spr:pharmo:v:3:y:2019:i:1:d:10.1007_s41669-018-0085-0
    DOI: 10.1007/s41669-018-0085-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-018-0085-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-018-0085-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:3:y:2019:i:1:d:10.1007_s41669-018-0085-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.